Arteritis de células gigantes
| Agente | Año | Tipo de estudio | Pacientes (n) | TR (n) | Casos adversos | Recaída | Muertes |
|---|---|---|---|---|---|---|---|
| INFLIXIMAB | 2007 |
A |
28 |
12 |
20 |
16 |
0 |
| % | 42,857143 |
71,4285714 |
|||||
| INFLIXIMAB | 2001 |
D |
4 |
4 |
0 |
1 |
0 |
2002 |
D |
1 |
1 |
0 |
0 |
0 |
|
2003 |
D |
2 |
2 |
0 |
2 |
0 |
|
2005 |
D |
1 |
1 |
0 |
0 |
0 |
|
2007 |
D |
1 |
1 |
0 |
0 |
0 |
|
| Total | 9 |
9 |
0 |
3 |
0 |
||
| % | 100% |
0% |
|||||
| ETANERCEPT | 2003 |
D |
1 |
1 |
0 |
1 |
0 |
2007 |
A |
8 |
4 |
8 |
0 |
0 |
|
| Total | 9 |
5 |
8 |
1 |
0 |
||
| RITUXIMAB | 2005 |
D |
1 |
1 |
1 |
0 |
0 |
2007 |
D |
1 |
1 |
0 |
0 |
0 |
|
| Total | 2 |
2 |
1 |
0 |
0 |
||
| ADALIMUMAB | 2007 |
D |
1 |
1 |
0 |
0 |
0 |
| Total | 1 |
1 |
0 |
0 |
0 |